Дефлацакорт — синтетический глюкокортикоид с меньшими побочными эффектами?

1. Adinoff A.D., Mollister J.R. Steroid-induced fractures and bone less in patients with asthma / / N. Engl. J. Med.— 1983.— Vol.309.— P.265—268.

2. Aicardi G., Milani S., Imbimbo B., Vignolo M ., Di-Battista E., Gusmano R. Comparison of growth retarding effects induced by two different glucocorticoid in prepubertal sick children: an interim long-term analysis / / Calcif. Tissue Int.— 1991.— Vol.48, № 4.— P.283—287.

3. American Medical Association. Adrenal Corticosteroids in Nonendocrine Diseases. Drug Evaluations.— Chicago, 1986.— P. 1089—1104.

4. Ansell B.M. Juvenile rheumatoid arthritis, juvenile chronic arthritis and juvenile spondyloarthropathies / / Curr. Opin. Rheumatol.— 1992.— Vol.4, № 5.— P.706—712.

5. Avioli L.V. Potency ratio — a brief synopsis / / Br. J. Rheumatol.— 1993.— Vol.32, Suppl.2.— P.24—26.

6. Axelrod L. Glucocorticoid therapy / / Medicine.— 1976.— Vol.55.— P.39—65.

7. Babadjanova G., Schulte H.M., Kjos-Potsch K., Reincke M., Allolio B. Is deflazacort less diabetogenic than prednisolone? / / Exp. Clin. Endocrinol.— 1996.— Vol.104, Suppl.l.— P.144.

8. Babadjanova G., Allolio B., Vollmer M., Reincke M., Schulte H.M. Comparison of the pharmacodynamic effects of deflazacort and prednisalone in healthy subjects / / Eur. J. Clin. Pharmacol.— 1996.— Vol.51, № 1.— P.53—57.

9. Boyce B.F., Aufdemorte T.B., Garrett I.R., Yates A.J.R., Mundy G.R. Effects of interleukin-1 on bone turnover in normal mice / / Endocrinology.— 1989.— Vol.125.— P.1142.

10. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors / / Nature.— 1986.— Vol.319.— P.516.

11. Brown J.P., Malaval L., Chapuy M.C., Delmas P.O., Eduardo C., Meunier P.J. Serum bone Gla-protein: A specific marker of bone formation in post-menopausal osteoporosis / / Lancet.— 1984.— V o l.l.— P.1091 — 1093.

12. Bruno A. / / Glococorticoid Effects and Their Biological Consequences: Advances in Glucocorticoid Therapy / Ed. L. V. Avioli.- Amsterdam: Excepta Medica, 1986.— P.79.

13. Bruno A., Cavallo-Perin P., Cassader M., Pagano G. Deflazacort vs Prednisone. Effect on blood glucose control in insulin-treated diabetics / / Arch. Intern. Med.— 1987.— Vol.147.— P.679—680.

14. Bruno A., Pagano G., Benzi L., Ciani G.Di., Spallone V., Calabrese G., Passeri A. Change in glucose metabolism after long-term treatment with deflazacort and bethamethason / / J. Clin. Pharmacol.— 1992.— Vol.43.— P.47—50.

15. Buniva G., Dubini A., Sassella D. Human bioassay of corticotrophin-suppressing / / Curr. Ther. Res.— 1979.— Vol.26.— P.69—81.

16. Canalis E., Avioli L. Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells / / J. Bone Miner. Res.— 1992.— Vol.7, № 9.— P. 1085—1092.

17. Cann J.W., Fajans S.S. Symposium of diabetes influence of adrenal cortical steroids on carbohydrate metabolism in man / / Metab. Clin. Exp.— 1956.— Vol.5.— P.l14—121.

18. Dambacher M.A., Olah A.I., Maurer M., Gampp R., Ruegsegger P. Pathogenesis prevention and therapy of steroid osteoporosis / / Z. Ortop.— 1990.— Bd 128, № 3.— S.234—239.

19. David J., Loftus I., Hesp R., Ansell B.M., Reeve J., Woo R.M. Spinal and somatic growth in patients with juvenile chronic artritis theated for up to 2 years with deflazacort / / Clin. Exp. Rheumatol.— 1992.— Vol.10, № 6.— P.621—624.

20. Evans D.B., Bunning R.A.D., Russell R.G.G. The effects of human interleukin-1 b on cellular proliferation and the production of prostaglandin E2 plasminogen activator, osteocalcin and alkaline phosphatase by osteoblast — like cells derived from human / / Biochem. Biophys. Res. Commun.— 1990.— Vol. 166, № 1.— P.208—216.

21. Falcini F., Taccetti G., Trapani S., Tafi L., Volpi M. Growth retardation in juvenile chronic arthritis patients treated with steroids / / Clin. Exp. Rheumatol.— 1991.— Vol.9, № 6.— P.37—40.

22. Ferrari A., Pasqualetti D., Del-Bianco P., Gandolfo G.M., Christolini A., M azzacconi M.G. Prednisone versus deflazacort in the treatment of autoimmune thrombocytopenic purpura: evaluation of clinical responce and immunological modifications / / Haematologica.— 1991.— Vol.76, № 4.— P.342—345.

23. Ferraris J.R., Day P.F., Gutwan R., Granillo E., Ramirez J., Ruiz S., Pascualini T. Effect of therapy with new glococorticoid, deflazacort, on linear growth and growth-hormone secretion after renal transplantation / / J. Pediatr.— 1992.— Vol.121, № 5. pt i. p.809—813.

24. Filipponi P., Blass A. Deflazacort: a new glucocorticoid / / Drugs Today.— 1987.— Vol.6.— P.329—334.

25. Gallagher J.C., Aaren J., Horsman A., Wilkinson R., Nordin B.E.C. Corticosteroid osteoporosis / / Clin. Endocrinol. Metab.— 1973. - Vol.2.— P.355—368.

26. Gennari C., Imbimbo B., Montagnini M., Bernini M., Nardi P., Avioli L.V. Effects of prednisone and deflazacort on mineral metabolism and parathyreoid activity in humans / / Calcif. Tissue Int.— 1984.— Vol.36.— P.245—252.

27. Gowen M., Chapman K., Littlewood A., Hughes D.E., Evans D.B., Russell R.G.G. Production of tumour necrosis factor by human osteoblasts is modulated by other cytokines but not by osteotropic hormones / / Endocrinology.— 1990.— Vol. 126.— P. 1250.

28. Gray R.E.S., Doherty S.M., Galloway J., Coulton L., de Broe M., Kanis J.A. A doubleblind study of deflazacort and prednisone in patients with chronic inflammatory disorders / / Arthr. Rheum.— 1991.— Vol.34.— P.287—296.

29. Gray R., Harrington C., Coulton L., Galloway J., de Broe M., Kanis J. Long-term treatment of chronic inflammatory disorders with deflazacort / / J. Orthopaed. Rheumatol.— 1990.— Vol.3.— P. 15—27.

30. Gundberg C.M., Grant F.D., Conlin P.R., Chen C.J., Brown E.M., Johnson P.J., Leboff M.S. Acute changes in serum osteocalcin during induced hypocalcemia in humans / / J. Clin. Endocrinol. Metab.— 1991.— Vol.72.— P.438—443.

31. Hahn T.J., Halstead L.R., Teitelbaum S.L., Hahn B.H. Altered mineral metabolism in glucocorticoid-induced osteoporosis. Effect of 25-hydroxyvitamin D administration / / J. Clin. Invest.— 1979.— Vol.64.— P.655—665.

32. Hahn B.H. et al. Immunosuppressive effects of deflazacort — a new glucocorticoid with bone-sparing and carbohydrate-sparing properties: comparison with prednisone / / J. Rheumatol.— 1981.— Vol.8.— P.783—790.

33. Heifer E.L., Rose L.I. Corticosteroids and adrenal suppression / / Drugs.— 1989.— Vol.38, № 5.— P.838—845.

34. Hench P.S., Kendall E.C., Hocumb C.H., Polley H.F. Effect of a hormone of the adrenal cortex (17-hydroxy-l 1-dehydrocorticosterorone; compound 6) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis; preliminary report / / Proc. Mayo Clin.— 1948.— Vol.24.— P.181 — 197.

35. Hodsman A.B., Toogood J.H., Jennings B., Fraker L.J., Baskerville J.C. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin / / J. Clin. Endocrinol. Metab.— 1991.— Vol.72, № 3.— P.530—540.

36. Joffe J., Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management / / Semin. Arthr. Rheum.— 1991.— Vol.20, № 4.— P.256—272.

37. Jowsey J., Kelly P.J., Riggs B.L., Bianco A.J., Scholz D.A. Quantitative and microradiographic studies of normal and osteoporotic bone / / J. Bone Jt Surg.— 1965.— Vol.47A.— P.785—806.

38. Kobberling J., Rotenberger J. Problems in evaluating dose equivalences of glucocorticoids / / Int. J. Clin. Pharmacol.— 1992.— Vol.30.— P.434—436.

39. Kotowicz M.A., Halls S., Hunder G.G., Cedel L., Mann K.G., Riggs B.L. Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders / / Arthr. Rheum.— 1990.— Vol.33.— P.1487—1492.

40. Littlewood A.J., Aarden L.A., Evans D.B., Russel R.G.G., Gowen M. Human osteoblast-like cells do not respond to interleukin-6 / / J. Bone. Miner. Res.— 1991.— Vol.6.— P.141.

41. Lo Cascio V., Francia G., Davi M.V., Olivieri M., Adami S., Cominacini L., Rossi L. Effect of deflazacort on growth hormone respons to insulin tolerance test / / Horm. Metab. Res.— 1992.— Vol.24, № 7.— P.333—335.

42. Loftus J., Allen R., Mesp J., David D.M., Reid D.J. Randomized, double-blind trial of deflazacort versus prednisolone in juvenille chronic (or rheumatoid) arthritis: a relatively bone-sparing effects of deflazacort / / Pediatrics.— 1991.— Vol.88, № 3.— P.428—436.

43. Lund B., Egsmose C., Jorgensen S., Krogsgaard M.R. Establishment of the relative antiinflammatory potency of deflazacort and prednison in polymyalgia rheumatica / / Calcif. Tissue Int.— 1987.— Vol.41.— P.316—320.

44. Mackie E.J., Treschel U. Stimulation of bone formation in vivo by transforming growth factor-b: remodelling of women bone and lack of inhibition by indomethacin / / Bone.— 1990.— Vol.l 1.— P.295.

45. Martin M.M., Gaboardi F., Podalsky S., Raiti S., Calcagno P.L. Intermitt steroid therapy. 1st effect on hypothalamic-pituitary-adrenal function and the response of plasma growth hormone and insulin to stimulation / / N. Engl. J. Med.— 1968.— Vol.279.— P.273—27S.

46. Martinelli E ., Ferrari P., Ripamonti A., Tuan G., Perazzi A., Assandri A. Metabolism of deflazacort in the rat, dog and man / / Drug. Metab. Disp.— 1979.— Vol.7.— P.335—339.

47. Mathur A., Kremer J.M. Immunopathology, muscu features and treatment of sarcoidosis / / Curr. Opin. Rheumatol.— 1993.— Vol.5, № 1.— P.90—94.

48. Me Ewen B.S. Non-genomic and genimic effects of steroids on neutral activity / / Trends Pharmacol. Sci.— 1991.— Vol. 12.— P.141 — 147.

49. Meikle A.W ., Clark D.M., Tyler F.H. Cushing syndrome from low doses of dexamethason / / J. Am. Med. Assoc.— 1976.— Vol.235.— P. 1592—1593.

50. Melby J.C. Systemic corticosteroid therapy: Pharmacologic and endocrinologic considerations / / Ann. Intern. Med.— 1974.— Vol.81.— P.505—512.

51. Messina O.D., Barreira J.C., Zanchetta J.R., Maldonado-Coceo J.A., Bogado G.E., Sebastian O.N., Flores D., Riopedre A.M., Redondo G., Lazaro A. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis / / J. Rheumatol.— 1992.— Vol. 19, № 10.— P. 1520—1526.

52. Montecucco C., Baldi F., Fortina A., Tomassini G., Caporali R., Cherie-Ligniere E.L., Fratino P. Serum osteocalcin (bone GlaProtein) following corticosteroid therapy in postmenopausal women with rheumatoid athritis. Comparison of the effect of prednisone and deflazacort / / Clin. Rheumatol.— 1988.— Vol.7, № 3.— P.366—371.

53. Montecucco C., Caporali R., Caprotti P., Caprotti M., Notario A. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids / / J. Rheumatol.— 1992.— Vol.19, № 12.— P.1895—1900.

54. M undy G.R. Lokal factors in bone remodelling / / Rec. Prog. Horm. Res.— 1989.— Vol.45.— P.507—531.

55. Muruais C., Cordido F., Morales M.J., Casanueva F.T., Dieguez C. Corticosteroid-induced growth hormone secretion in normal and obese subjects / / Clin. Endocrinol.— 1991.— Vol.35, № 6.— P.485—490.

56. Nelson A.M., Conn D.L. Series of pharmacology in practice. 9. Glucocorticoids in rheumatic disease / / Mayo Clin. Proc — 1980.— Vol.55.— P.758—769.

57. Nichols T., Nugent C.A., Tyler F.H. Diurnal variation in suppression of adrenal function by glucocorticoids / / J. Clin. Endocrinol. Metab.— 1965.— Vol.25.— P.343—349.

58. Nielsen H.K., Laubert P., Brixen K., Mosekilde L. Relation between diurinal variations in serum osteocalcin, cortisol, parathyroid hormone and ionized calcium in normal individuals / / Acta Endocrinol.— 1991.— Vol.124.— P.391— 399.

59. Noda M., Camillere J.J. In vivo stimulation of bone formation by transforming growth factors-b / / Endocrinology — 1989.— Vol.24.— P.2291.

60. Olefsky J.M. The insulin receptor: ist cell in insulin resistance of obesity and diabetes / / Diabetes.— 1976.— Vol.25.— P. 1091—1098.

61. Olgaard K., Strom T., Wowern N.V., Daugaard M., Egfjord M., Lewin E., Brandi L. Bone mineral content during treatment with deflazacort versus prednisone in nephrotic patients / / Official Satelite Symposium to the 22-nd European Symposium on Calcified Tissues.— Vienna, 1991.— P .10.

62. Olgaard K., Strom T., Wowern N.V., Daugaard M., Egfjord M., Lewin E., Brandi L. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort / / Calcif. Tissue Int.— 1992.— Vol.50.— P.490—497.

63. Olgaard K., Strom T., Wowern N.V., Daugaard M., Egfjord M.,Lewin E., Brandi L. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort / / Br. J. Rheumatol.— 1993.— Vol 32 Suppl.2.— P.15—23.

64. Pagano G., Bruno A., Cavallo-Perin P., Cesco L., Imbimbo B. Glucose intolerance after short-term administration of corticosteroids in healthy subjects / / Arch. Intern. Med.— 1989 — Vol.149.— P.1098—1101.

65. Prummel M.F., Wiersinga W.M., Lips P., Sanders G.T., Sauerwein H.P. The coerse of biochemical parameters of bone turnover during treatment with corticosteroids / / J. Clin. Endocrinol Metab.— 1991.— Vol.72.— P.328—336.

66. RabinovitchA., Suarez W.L., Power R.F. Combination therapy with an antioxidant and a corticosteroid prevents autoimmune diabetes in NOD mice / / Life Sci.— 1992.— Vol.51.— P. 1937—1943.

67. Raisz L.G. Steroids and ostroporosis: an unsolved problem? / / Klerekope M. et al. Clinical Disorders of Bone and Mineral Metabolism.— Amsterdam: Mary Ann Liebert, 1989.— P.211—217.

68. Reid J.R. Steroid osteoporosis / / Calcif. Tissue Int.— 1989 — Vol.45.— P.63—67.

69. Reid D.M., Kennedy N.S.I., Smith M .A., Tothill P., Nuki G. Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment / / Br. Med. J.— 1982.— Vol.285 — P.330—332.

70. Reifenstein E.C. The relationships of steroid hormones to the development of the management of osteoporosis in aging people / / Clin. Orthopaed. Relat. Res.— 1957.— Vol.l.— P.206—253.

71. Rizzato G., Fraioli P. Natural and corticosteroid induced osteoporosis in sarcoidosis: prevention, treatment, follow up and reversibility (editorial) / / Sarcoidosis.— 1990.— Vol.7, N° 2.— P.89—92.

72. Russell R.G.G., Dieppe P. Osteoarthritis.— London: IBC, 1991.

73. Russell R.G.G. Cellular regulatory mechanisms that may underlie the effects of corticosteroids on bone / / Br. J. Rheumatol — 1993.— Vol.32, N° 2.— P.6—10.

74. Russell R.G.G., Krane S.M. Editorial / / Ibid.— P .l—2.

75. Streck W.F., Lockwood D.M. Pituitary adrenal recovery following short-term suppression with corticosteroids / / Am. J. Med — 1979.— Vol.66.— P.910—914.

76. Trnavsky K. Pharmacotherapy of rheumatoid arthritis in 1992 / / Cas. Lek. Cesk.— 1992.— Vol. 13, N° 19.— P.588—592.

77. Vignolo M., Milani S., Imbimbo B., Naselli A., Di-Batista E., Piaggio G. Statural growth and skeletal maturation in rheumatic prepubertal children treated with a third generation glucocorticoid (deflazacort) versus prednisone. An interim study / / Clin. Exp. Rheumatol.— 1991.— Vol.9, № 6.— P.41—45.

78. Vollmer M., Babadjanova G., Monig H., Reincke M., Karl M., Allolio B., Schulte H.M. Pharmacodynamic effects of deflazacort versus prednisolone in healthy subjects / / Eur. J. Clin. Invest.— 1994.— Vol.24, Suppl.2.— P.52.

79. Wajchenberg B.L., Cesar F.P., Okada H., Torres J., LerarioA.C., Borghi V.C., Malerbo D.A.C., Filho A.G., Liberman B., Gianella D. Glucocorticoids, glucose metabolism and hypothalamic-pituitariadrenal axic / / Glucocorticoid Effects and Their Biological Cosequences / Eds L.V.Avioli, C.Gennari, B.Imbimbo.— New York: Plenum Press, 1984.— P.25—44.

80. Wozney J.M. Bone morphogenetic proteins / / Prog. Growth Factor Res.— 1989.— Vol.l.— P.267.

81. Zwaldo-Klarwasser G., Bent S., Haubeck H.D., Sorg S., Schmuthler W. Glucocorticoid-induced appearance of macrophage subtype RM 3/1 + in peripheral blood of man / / Int. Arch. Allergy Appl. Immunol.— 1990.— Vol.91.— P .175—180.